Given the synergy between drugs such as ibrutinib or lenalidomide and multiple agents uncovered thus far, it may eventually be possible to combine in a personalized manner conventional immuno-chemotherapeutic regimes with three, four or more novel single-agent drugs simultaneously inhibiting the most important oncogenic signaling pathways to overcome the aggressive nature of HR-and BCR-subtype ABC-DLBCL or other subtypes of relapsed/refractory DLBCLs and thereby ensure maximal efficacy while minimizing side effects. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.